Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Key Highlights
- ➤Phase 2a trial doses first patient in Australia for generalized anxiety disorder and sleep disturbance
- ➤Topline Phase 2a data expected in early 2028
- ➤Phase 1 showed GlyphAgo bioavailability 6.8-fold higher than unmodified agomelatine
- ➤Phase 2/3 GAD trial planned to begin in first half of 2027
- ➤Phase 2/3 topline data expected by end of 2028
Expert Statements
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Anxiety disorders affect more than 300 million people globally(3), and place a substantial burden on patients, families, and healthcare systems”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Patients with generalized anxiety disorder experience persistent anxiety symptoms that can make it difficult to carry out normal activities, and sleep disturbances are among the most frequently reported debilitating symptoms.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Despite the widespread impact of GAD, there have been no new approved therapies in almost two decades, and many patients continue to experience inadequate symptom relief or tolerability issues that limit treatment.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“The initiation of this trial is an important step in bringing this potential new medicine to patients and their families.”
Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics
“Agomelatine has been shown to improve sleep quality and sleep architecture without the daytime sleepiness seen with other therapies, making it a compelling candidate for patients with GAD and sleep disturbance”
Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics
“We designed GlyphAgo with our Glyph(TM) platform to bypass first-pass liver metabolism and address the bioavailability and hepatic limitations of unmodified agomelatine.”
Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics
“We believe that GlyphAgo represents a potentially important treatment advance for people with GAD.”
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo(TM) in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Trial is designed to demonstrate proof-of-pharmacology by evaluating the effects of GlyphAgo on sleep and anxiety symptoms in patients with generalized anxiety disorder
Get started
Create a free account to read the full story.